ABIVAX To Participate in the Upcoming RBC Capital Markets 2016 Healthcare Conference in New York, and in the Credit Suisse Healthcare Conference in London

Regulatory News:

ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its CEO, Prof. Hartmut Ehrlich, M.D., will participate in the RBC Capital Markets 2016 Healthcare Conference in New York on February 23^rd and 24^th, and in the Credit Suisse Healthcare Conference in London on March 1^st and 2^nd.

At the RBC Capital Markets 2016 Healthcare conference, Prof. Ehrlich is scheduled to participate in a fireside chat with RBCCM healthcare analyst Douglas Miehm at 8:30 AM (EST) on February 23rd. This conversation will be webcast, and will be available on ABIVAX’s website. Additionally, Prof. Ehrlich and ABIVAX’s CFO, Alain Chevallier, will conduct one-on-one meetings with interested investors over the course of the conference.

At the Credit Suisse Healthcare conference in London, Prof. Ehrlich and Mr. Chevallier will meet with investors in one-on-one meetings over the course of the conference.

ABIVAX (www.abivax.com) is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and vaccines to treat some of the world’s most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months.
Follow us on Twitter @ABIVAX_

View source version on businesswire.com: http://www.businesswire.com/news/home/20160211006035/en/